Quantum Biopharma (QNTM) Cash from Financing Activities (2019 - 2026)

Quantum Biopharma's Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $7.0 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 123.35% year-over-year to $7.0 million; the TTM figure through Mar 2026 stood at $10.0 million (down 29.75% YoY), while the FY2025 annual figure was $6.1 million, down 47.51% from the prior year.
• Cash from Financing Activities came in at $7.0 million for Q1 2026 at Quantum Biopharma, up from $1.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $7.0 million in Q1 2026 to a low of -$4.1 million in Q4 2022.
• A 4-year average of $1.7 million and a median of $1.4 million in 2025 frame the typical range for Cash from Financing Activities.
• On a YoY basis, Cash from Financing Activities climbed as much as 450.97% in 2025 and fell as far as 96.12% in 2025.
• Quantum Biopharma's Cash from Financing Activities stood at -$4.1 million in 2022, then jumped by 160.34% to $2.5 million in 2024, then tumbled by 42.68% to $1.4 million in 2025, then soared by 394.82% to $7.0 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $7.0 million, $1.4 million, and $261425.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison